Post-Dilution Hemodiafiltration With a Heparin-Grafted Polyacrylonitrile Membrane

• Published in: Therapeutic apheresis and dialysis 2015-04, Vol.19 (2), p.154-161
• Main Authors: Frascà, Giovanni M, Sagripanti, Sibilla, D'Arezzo, Mario, Oliva, Simonetta, Francioso, Angelo, Mosconi, Giovanni, Zambianchi, Loretta, Sopranzi, Franco, Boggi, Rolando, Fattori, Laura, Rigotti, Angelo, Maldini, Laura, Gattiani, Andrea, Del Rosso, Goffredo, Federico, Antonio, Da Lio, Lidia, Ferrante, Luigi
• Format: Article
• Language: English
• Subjects: Acrylic Resins - therapeutic use; Adult; Aged; Aged, 80 and over; Anticoagulation; Female; Fibrinolytic Agents - therapeutic use; Hemodiafiltration; Hemodiafiltration - instrumentation; Hemodiafiltration - methods; Heparin; Heparin, Low-Molecular-Weight - therapeutic use; HeprAN; Humans; Italy; Kidney Failure, Chronic - therapy; Male; Membranes, Artificial; Middle Aged; Polyacrylonitrile membrane; Prospective Studies; Treatment Outcome; Young Adult
• ISSN: 1744-9979; 1744-9987
• DOI: 10.1111/1744-9987.12230

The aim of this multicenter, prospective study was to explore the possibility of carrying out routine sessions of post‐dilution hemodiafiltration with a polyacrylonitrile membrane grafted with heparin (HeprAN) and reduced anticoagulation. Forty‐four patients from eight centers were included in the study and treated by means of post‐dilution on‐line hemodiafiltration with automatic control of TMP, according to three different modalities tested consecutively: phase 1, polyethersulfone filter primed with heparinized saline and anticoagulated with continuous infusion of unfractionated heparin 1000/h; phase 2, HeprAN membrane filter primed with saline without heparin. Anticoagulation: a 1000‐unit bolus of unfractionated heparin at the start of session followed by a second one at the end of the second dialysis hour; phase 3, same filter and priming procedure as in phase 2; anticoagulation with nadroparin calcium at the beginning of treatment. Partial or massive clotting of the dialyzer occurred in less than 1% of sessions in phase 1; 10% and 7% in phase 2; and 1% and 2% in phase 3. Clotting limited to the drip chambers was observed in 13%, 34% and 12%, respectively. The study of coagulation parameters showed a better profile when low‐molecular weight heparin (LMWH) was used in association with HeprAN membrane, while the generation of TAT complexes did not differ from that observed with the standard anticoagulation modality used in phase 1. Our results suggest that the HeprAN membrane can be used safely in routine post‐dilution hemodiafiltration with reduced doses of LMWH.